Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.51 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22392128 | 1.00 | AHR (0.51) | AHRSUCNR1CFTRADORA3SCN10A | |
| SCHEMBL22430121 | 0.86 | AHR (0.69) | AHRSUCNR1CFTRADORA3SCN10A | |
| SCHEMBL25580216 | 0.86 | AHR (0.69) | AHRSUCNR1CFTRADORA3SCN10A | |
| SCHEMBL21001328 | 0.85 | AHR (0.53) | AHRSUCNR1CFTRADORA3SCN10A | |
| SCHEMBL21001686 | 0.84 | AHR (0.50) | AHRSUCNR1CFTRADORA3SCN10A | |
| SCHEMBL21001687 | 0.84 | AHR (0.50) | AHRSUCNR1CFTRADORA3SCN10A | |
| SCHEMBL21011977 | 0.84 | AHR (0.61) | AHRSUCNR1ADORA3SCN10ASCN2A | |
| SCHEMBL21011978 | 0.84 | AHR (0.61) | AHRSUCNR1ADORA3SCN10ASCN2A | |
| SCHEMBL22391740 | 0.84 | AHR (0.56) | AHRSUCNR1ADORA3SCN10ASCN2A | |
| SCHEMBL22391906 | 0.83 | AHR (0.57) | AHRSUCNR1ADORA3SCN10ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524944-B2 | 2-phenylpyrimidine-4-carboxamides as AHR inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-13 | — | — | US | claimed |
| EP-3713923-B1 | 2-PHENYLPYRIMIDINE-4-CARBOXAMIDES AS AHR INHIBITORS | BAYER AG (DE) | 2021-12-01 | — | — | EP | claimed |
| US-20200283395-A1 | 2-PHENYLPYRIMIDINE-4-CARBOXAMIDES AS AHR INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2020-09-10 | — | — | US | claimed |
| US-11524944-B2 | 2-phenylpyrimidine-4-carboxamides as AHR inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-13 | — | — | US | disclosed |
| US-11524944-B2 | 2-phenylpyrimidine-4-carboxamides as AHR inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-13 | — | — | US | disclosed |
| EP-3713923-B1 | 2-PHENYLPYRIMIDINE-4-CARBOXAMIDES AS AHR INHIBITORS | BAYER AG (DE) | 2021-12-01 | — | — | EP | disclosed |
| US-20200283395-A1 | 2-PHENYLPYRIMIDINE-4-CARBOXAMIDES AS AHR INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2020-09-10 | — | — | US | disclosed |
| US-20200283395-A1 | 2-PHENYLPYRIMIDINE-4-CARBOXAMIDES AS AHR INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283395-A1 | 2-PHENYLPYRIMIDINE-4-CARBOXAMIDES AS AHR INHIBITORS | AHR, ARNT, IDO1 | AHR 1/4885SUCNR1 1165/4885CFTR 748/4885 |
| US-11524944-B2 | 2-phenylpyrimidine-4-carboxamides as AHR inhibitors | AHR, ARNT, IDO1 | AHR 1/4885SUCNR1 1165/4885CFTR 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.